BioSpace News Archive

Auburn University research and the heart-wrenching experience of an Opelika, Alabama, couple are providing hope to children facing the deadly genetic disease, GM1 gangliosidosis.

SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that management will participate in the upcoming 31st Annual Piper Jaffray Healthcare Conference in New York.

FLX475 is an oral, small molecule CCR4 antagonist in development for the treatment of multiple cancers.

Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Company presentation at the 31st Annual Piper Jaffray Healthcare Conference

Strategic transaction enables Veracyte to access global markets through a world-class, distributed instrument system, with an initial focus on its pulmonology franchise

Xenon Pharmaceuticals Inc. announced that Dr. Simon Pimstone, Xenon’s Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference in New York, NY on Wednesday, December 4, 2019 at 3:00 pm Eastern Time.

Johnson & Johnson Consumer Inc. reaffirmed that its Johnson’s Baby Powder is safe and free of asbestos after a comprehensive investigation into the United States Food and Drug Administration’s earlier reported finding of sub-trace levels of asbestos in samples from a single bottle of Johnson’s Baby Powder.

Approval based on the Phase III IMpower130 study showing the Tecentriq plus chemotherapy combination demonstrated a significant overall survival and progression-free survival benefit

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that multiple studies will be presented at the 2019 San Antonio Breast Cancer Symposium (SABCS) being held Dec. 10-14, 2019 in San Antonio, Tx.

Multinational study in the U.S., Israel and Europe targeting to be the first product candidate supporting muscle regeneration after significant trauma such as hip fracture